Novo Nordisk released data Wednesday showing that patients taking its new medication, a pill known as amycretin, lost up to 13% of their body weight after 12 weeks, with mild to moderate side effects. The data from the Phase I study was presented at the European Association for the Study of Diabetes meeting in Madrid.

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise